Apexigen Inc., J&J deal

Apexigen partnered with Johnson & Johnson's Centocor Research and Development Inc. subsidiary to discover and develop mAbs. Apexigen will screen antibodies against undisclosed targets supplied by Centocor, which will be responsible for further development and commercialization of any antibodies identified. Apexigen will receive an upfront payment and is eligible for milestones and royalties. Further financial terms were not disclosed. ...